The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis. The results are ...

Takeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used ...

Vedolizumab (Entyvio) was superior to adalimumab (Humira) for clinical remission and endoscopic mucosal healing in moderate-to-severe active ulcerative colitis at 52 weeks, according to a presentation ...

- ENTYVIO ® superior to Humira ® in achieving clinical remission and mucosal healing at week 52 in patients with moderately to severely active ulcerative colitis OAKVILLE, ON, March 11, 2019 /CNW/ - ...

Takeda (TAK) is running a Phase 4 study in adults with moderate to severe Crohn’s disease to test dual targeted therapy with Entyvio (vedolizumab) plus Humira (adalimumab) or Stelara (ustekinumab), ...

The FDA announced a new contender in the ulcerative colitis and Crohn’s disease treatment space: Takeda, which scored approval of its infusion drug Entyvio for adults with moderate-to-severe forms of ...

Takeda is finally over the hump with its inflammatory bowel disease drug Entyvio after safety questions threatened its approval. And while the drug will take a backseat to a few of the market's ...

Takeda’s key growth product Entyvio has outperformed AbbVie’s Humira in a trial in ulcerative colitis (UC), said to be the first head-to-head comparison of biologic drugs for the condition. The ...